Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Give their signed written informed consent to participate~2. Are at least 40 years of age and no older than 80 years~3. COPD patients who are symptomatic~4. Must be receiving one or more inhaled bronchodilators as maintenance therapy~Exclusion Criteria:~1. Current diagnosis of asthma,~2. COPD due to α1-Antitrypsin Deficiency~3. Known active tuberculosis, lung cancer, cystic fibrosis, significant bronchiectasis, Pulmonary resection or Lung Volume Reduction Surgery during the past 6 months~4. Long-term-oxygen therapy (≥ 12 hours a day).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BFF MDI 320/9.6 μg (Type: EXPERIMENTAL): Budesonide and Formoterol Fumarate Inhalation Aerosol 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
- BFF MDI 160/9.6 μg (Type: EXPERIMENTAL): Budesonide and Formoterol Fumarate Inhalation Aerosol-80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
- FF MDI 9.6 μg (Type: EXPERIMENTAL): Formoterol Fumarate Inhalation Aerosol-4.8 μg per actuation MDI/ 120 inhalations Taken as 2 inhalations BID
- BD MDI 320 μg (Type: EXPERIMENTAL): Budesonide inhalation Aerosol 160 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
- Symbicort® TBH 400/12 μg (Type: OTHER): Symbicort Turbuhaler 400/12 μg Taken as 2 inhalations BID

Based on this trial design, predict the completion outcome and termination type (if applicable).